Healthcare
Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage
About this update from Grail, Inc.
MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with GRAIL to become the first Michigan health plan to enable its employer groups to easily add the Galleri test to their existing cancer screening coverage. Priority Health is a nationally recognized nonprofit health plan serving more than 1.4 million members across Michigan and beyond. As a comprehensive health plan offering fully funded, self-funded, level-funded and third-party administrator (TPA) models, Priority Health provides employers with the flexibility to design customized benefit programs that integrate its extensive provider network, care management services, pharmacy benefits and stop-loss coverage options. "Early cancer detection can lower health care costs by enabling less intensive, more effective treatments. By adding Galleri to recommended single-cancer screenings, GRAIL has the unique opportunity to help define a new standard of care and help prevent costly late-stage care and potentially improve patient outcomes through earlier, asymptomatic cancer detection," said Megan Hall, PhD, vice president of Medical Affairs at GRAIL. "Priority Health is leading the way in innovative employee benefit offerings, and we are excited to collaborate to bring Galleri to their customers while expanding broader market access." Single-cancer screenings are an important tool for detection and diagnosis of five cancers in the U.S, but 70% of cancer deaths are caused by cancers without recommended screening tests. With a simple blood draw, Galleri screens for many of the deadliest cancers before symptoms appear — when they can be treated more easily and are potentially curable. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up. Galleri is supported by rigorous studies in intended use populations and is the only available MCED test with demonstrated performance in patients being screened for cancer.